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a b s t r a c t
Chronic myelogenous leukemia (CML), in the Chronic Phase (CP), is often suspected as a result of a
complete blood count (CBC), which shows increased granulocytes, mostly mature including a peak in
myelocytes, increased basophils, and rarely blasts and/or promyelocytes. Morphologic dysplasia is not
present. CML is conﬁrmed by detecting the characteristic Philadelphia chromosome (Ph)[t(9;22)(q34;
q11.2)] by routine cytogenetics or ﬂuorescent in situ hybridization (FISH) or molecular studies (RT-PCR)
for the bcr-abl fusion gene.
The most common feature of CML is an elevated WBC count, usually above 25103/µL, and
frequently above 100103/µL. We report a case of conﬁrmed PhþCML with a normal CBC detected
because of the presence of rare myelocytes and 2% basophils [Fig. 1]. Previous leukocyte counts for the
preceding eight years were normal with the exception of one done four months prior to his presentation
that showed an abnormal differential with 1% basophils, 2% metamyelocytes and 2% myelocytes.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Case Report
A 65-year-old man with a past medical history of morbid
obesity, hypertension, paroxysmal atrial ﬁbrillation, depression
and arthritis developed substernal chest pressure and palpitations
and presented to the emergency department in September 2013
for evaluation. The patient denied fever, night sweats, anorexia or
unintentional weight loss. He denied tobacco or alcohol use. His
family history was signiﬁcant for renal cancer in his mother, breast
cancer and lung cancer in his sisters, diffuse large B cell lymphoma
in his brother, colon cancer in his maternal grandfather, head and
neck cancer in his paternal grandmother, bladder cancer in his
maternal uncle, and childhood leukemia in a nephew.
The general physical examination revealed an obese man with
a heart rate of 140/minute but was otherwise unremarkable. The
cardiac exam revealed an irregular rhythm. The abdominal exam
revealed no tenderness or hepatosplenomegaly. A complete blood
count (CBC) was performed and the results of the CBC are outlined
in Table 1.
Evaluation of the peripheral blood smear revealed a mild baso-
philia (2%) and myelocytes (1%) and meta myelocytes (1%). A
hematology consultation was requested for evaluation. A bone
marrow aspiration and biopsy was performed in October 2013.
Examination of the marrow revealed a slightly hypercellular marrow
with a granulocytic hyperplasia [Fig. 2]. Rare monolobated mega-
karyocytes were present. Karyotype analysis revealed 46, XY, t(9;22)
(q34;q11.2) in 20 cells analyzed and was the sole abnormality
observed. FISH performed with the ABL1/BCR probe identiﬁed the
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Table 1
Baseline blood counts.
Laboratory data September 2013
WBC (103/mL) 10.6
RBC (106/mL) 4.4
Hemoglobin (g/dl) 12.7
HCT (%) 40
MCV (ﬂ) 91
RDW (%) 15.7
Platelet count (103/mL) 254
Differential
Neutrophils # 8.1
Lymphocytes # 1.3
Monocytes # 0.4
Eosinophils # 0.2
Basophils # 0.3
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fusion of the ABL on chromosome 9 with the BCR gene on chromo-
some 22 in 90.5% of the metaphases. Quantitative Reverse
Transcriptase-Polymerase Chain Reaction analysis revealed the pre-
sence of the BCR-ABL transcript (p210 form) in 162/200 (81.0%) cells
scored.
The patient was diagnosed with chronic phase CML. The initial
hematology opinion recommended initiating tyrosine kinase inhi-
bitor therapy, and the patient sought a second opinion. Consider-
ing his asymptomatic presentation and stable blood counts, the
treating physicians supported a plan of active surveillance with
periodic CBCs and differential and LDH. He was last seen in August
2014. He remains asymptomatic with essentially stable blood
counts [Table 2].
2. Discussion
CML was the ﬁrst malignancy to be linked to a clear genetic
abnormality, the Philadelphia chromosome. This chromosomal
abnormality is so named because of the city in which it was ﬁrst
discovered and described in 1960 by Peter Nowell and David
Hungerford [1]. The fusion protein results in increased activity of a
tyrosine kinase and several other signal transduction pathways
with deregulation of the normal control mechanisms of granulo-
poiesis [2]. In most published series of consecutive patients
diagnosed with CML the total leukocyte counts are elevated [3].
In one recent series [4], 245 patients were analyzed and 178 of
these (72.6%) were in Chronic Phase. The mean total leukocyte
count was 168  109/L (range:35–959).
In 1972 Canellos and Whang-Peng [5] reported on a 43-year-
old male with a leukocyte count of 8800/cmm but 6% metamye-
locytes and 7% myelocytes. Examination was normal. The Ph was
detected in 22% of the metaphases and the patient remained
asymptomatic for ﬁve years without treatment before developing
a blast crisis. A second case was reported more recently by Hudnall
and coworkers from the University of Texas, Galveston. [6] Their
case was complicated by the simultaneous presentation of Hodgkin
lymphoma, Stage III, successfully treated. The total leukocyte count
remained normal for 15 months after recognition of the BCR-ABL
transcript.
The “containment” of these patients’ granulocyte proliferation
remains a mystery.
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Fig. 1. Basophil and metamyelocyte. Peripheral blood ﬁlm. Wright-Giemsa stain: 1000x.
Fig. 2. a. Numerous granulocytes without dysplasia: bone marrow aspirate: Wright-Giemsa Stain. 1000x b. Bone marrow biopsy: hypercellular particle with granuloctyic
predominance. Hematoxylin & Eosin Stain. 400x.
Table 2
Periodic blood counts.
Laboratory
data
November
2013
December
2013
February
2014
April
2014
June
2014
August
2014
WBC (103/mL) 10.2 9.2 7.2 7.8 13.7 11.8
RBC (106/mL) 4.22 3.87 3.97 4.54 4.47 4.1
Hemoglobin
(g/dl)
12.9 11.8 11.9 13.5 13.3 12.4
HCT (%) 40 36 37 41 41 38
MCV (ﬂ) 94 92 94 91 91 92
RDW (%) 15.4 14.9 14.5 14.8 15.3 15.2
Platelet count
(103/mL)
250 248 301 263 285 266
Differential
Neutrophil# 7.1 6 4.8 4.4 10 7
Lymphocyte# 1.5 1.8 1.4 1.9 1.5 2.8
Monocyte# 1.2 0.7 0.7 0.9 1.2 1.2
Eosinophil# 0.2 0 0 0.3 0.5 0
Basophil# 0.1 0.3 0.1 0.2 0.3 0.5
LDH 243 252 242 205 274 263
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